What is it about?
The article explores how does the differences in expression of genes related to drug metabolism, activation and action affect the success of treatment among acute myeloid leukemia (a type of blood cancer) patients.
Featured Image
Why is it important?
The study of various molecular markers underlying drug action in a single cohort help us understand better the effects of gene expression in blood cancer patients. This is very important because the drugs in question are those which are prescribed most commonly in this variety of deadly disease.
Perspectives
This is an interesting study that helped us understand how drug efficacy might change in a deadly disease, especially when such investigations are not routinely performed to predict drug response. We hope that this would help progress in the direction of personalized medicine to effectively save lives.
Dr Nasir Ali Afsar
Jinnah Medical & Dental College Karachi; Alfaisal University Riyadh.
Read the Original
This page is a summary of: Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin, Cancer Management and Research, November 2018, Dove Medical Press,
DOI: 10.2147/cmar.s181299.
You can read the full text:
Contributors
The following have contributed to this page
